Viewing Study NCT07285018


Ignite Creation Date: 2025-12-25 @ 4:46 AM
Ignite Modification Date: 2025-12-26 @ 3:47 AM
Study NCT ID: NCT07285018
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-16
First Post: 2025-12-09
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Sponsor: Eli Lilly and Company
Organization:

Study Overview

Official Title: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Diabetic Peripheral Neuropathic Pain
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: NP07
Brief Summary: The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
H0P-MC-NP07 OTHER Eli Lilly and Company View
H0P-MC-CPMP OTHER Eli Lilly and Company View